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The addition of femoral-femoral c rdiopulmonary bypass in 
the catheterization laboratory tosupport the high risk patient 
is a challenging new frontier for percutaneous transluminal 
coronary angioplasty. This new procedure isreported in this 
issue of the Journal in the form of an initial National Registry 
(1). Although their work is preliminary, the authors are to be 
congratulated for cooperating in this joint effort to obtain 
insight into subset suitability for the utilization of this unique 
invasive technique. This initial effort is reminiscent of the 
National Heart, Lung, and Blood Institute (NHLBI) registry 
started shortly after the introduction ofballoon angioplasty 
(2). The general experience suggests hat, as in any new 
therapeutic advance, risks must be weighed against benefits, 
and indications and contraindications need to be established 
clearly. 
In this regard, the use of cardiopulmonary support is 
inappropriate in cases of br;rderline myocardial dysfunction 
or where hemod;mamic instability would not be a serious 
consequence of angioplasty. This limitation is especially 
meaningful because of the 41% morbidity reported uring 
the learning curve in using cardiopulmonary support (1). 
Extensive arterial and venous incursions and significant 
blood loss occur in a disquieting number of patients. Pero- 
neal nerve injury also has been seen when percutaneous 
cannulation a d decannulation are utilized (3). 
Unresolved questkms md problems. There are unresolved 
questions reprding the manner of introductiorr and removal 
of the cannulas. At present, several centers are evaluating 
cohorts with total-percutaneous, total-open (surgical) can- 
nula introduction and removal or percutaneous cannula 
introduction with open removal in an effort to determine 
whether astatistical difference insuccess and, particularly, 
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function and multivessel 
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las should be removed soon after 
closure of more t
remaining vessel” is to undergo angioplasty under cardio- 
pulmonary support, one should choose relatively ideal (dis- 
crete, subtotal) lesions that have a high statistical chance of 
angioplasty success (6-8). Obviously, the lower the inci- 
dence of abrupt closure after the removal of the cannulas, 
the safer the overall procedure, specially if left ventricular 
function is morbidly depressed. It h?; always been true of 
high risk angioplasty hat the poorer the surgical risk, the 
more ideal the lesion should be for angioplasty. This is 
reemphasized in dealing with high risk patients having 
coronary angioplasty under cardiopulmonary support be- 
cause, as the authors (1) point out, four of the seven patients 
who had abrupt reclosure after decannulation died. 
Ms. Since this study was concluded 
(December 31, 1988), several additional observations have 
been noted. 
I) A b!ood flow of 6 liters/min may not be necessary; most 
patients have adequate perfusion with three to four liters/ 
min. Therefore, large cannulas could be replaced with 
smaller ones. With 18F (versus the initial 20F) cannulas, 
flows >4 literslmin can be maintained (without line cavita- 
tion) during the periods of dilation cat ation, 
(9). 
2) Rather severe underlying regional myocardial ischemia 
may develop during angioplasty despite cardiopulmonary 
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